KRAS and lung adenocarcinoma: A pooled analysis from three adjuvant chemotherapy trials of 295 patients with lung adenocarcinoma harboring KRAS wild-type and known EGFR status did not find a correlation between EGFR mutational status and prognosis or predictive value for OS and PFS [14].